Cargando…
MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA
BACKGROUND: Cell-free DNA (cfDNA) profiling has been shown to carry utility as a clinically relevant biomarker in a variety of cancers, but studies in pediatric brain tumors, including medulloblastoma, are scarce. We hereby evaluated the actionability of profiling cfDNA from cerebrospinal fluid (CSF...
Autores principales: | Liu, Anthony Pak-Yin, Kumar, Rahul, Kyle, Smith, Paul, Leena, Chintagumpala, Murali, Bouffet, Eric, Fisher, Michael J, Hassall, Tim, Gururangan, Sri, Hansford, Jordan, Cohn, Richard, Ellison, David W, Gilbertson, Richard J, Gajjar, Amar, Robinson, Giles W, Northcott, Paul A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715976/ http://dx.doi.org/10.1093/neuonc/noaa222.536 |
Ejemplares similares
-
MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
por: Northcott, Paul, et al.
Publicado: (2022) -
MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY
por: Chintagumpala, Murali, et al.
Publicado: (2020) -
MBRS-24. FUNCTIONAL CHARACTERIZATION OF IKBKAP/ELP1 AS A NOVEL SHH MEDULLOBLASTOMA PREDISPOSITION GENE
por: Lopez, Jesus Garcia, et al.
Publicado: (2020) -
MBRS-04. MEDULLOBLASTOMA DETECTION BY BLOOD TEST
por: Yalon, Michal, et al.
Publicado: (2020) -
MBRS-18. TUMOR SUPPRESSOR p53 DEFINES THE THERAPEUTIC RESPONSES IN TREATMENT OF MEDULLOBLASTOMA
por: Mohan, Avinash L, et al.
Publicado: (2020)